$192.91
▲ +0.0% Today
as of Jul 22, 16:53 ET
Last 30 days
Recent Press Releases & News
mixed
▲ 1
● 23
▼ 1
ResMed Earnings Growth Seen Strong as Ventilator Issue Clouds FY27, UBS Says
RBC Downgrades ResMed to Sector Perform From Outperform, Cuts Price Target to $234 From $276
Mizuho Adjusts Price Target on ResMed to $220 From $235, Maintains Outperform Rating
Overview
52-week range
$180
$294
11% of range
Avg surprise (last 2)
+2.0%
Avg reaction (last 1)
+0.2%
100% positive
Latest IV / EM
42%
EM ±9.6% · $195 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Mar 31, 2026 | Mar 2026 | $2.74 | — | — | — | — | financials |
| Wed Dec 31, 2025 | Dec 2025 | $2.68 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $2.37 | — | — | — | — | financials |
| Thu Jul 31, 2025 | Jun/2025 | $2.55 | $2.46 | +3.7% | — | — | earnings |
| Wed Apr 23, 2025 | Mar/2025 | $2.37 | $2.36 | +0.4% | — | +0.2% | earnings |
| Tue Dec 31, 2024 | Dec 2024 | $2.34 | — | — | — | — | financials |
| Mon Sep 30, 2024 | Sep 2024 | $2.11 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $2.04 | — | — | — | — | financials |
| Sun Dec 31, 2023 | Dec 2023 | $1.42 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $1.49 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | AMC | $2.90 | $2.55 | +13.7% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | $540M | $544M | $515M | — | $525M | $531M | $507M | — |
| Gross profit | $891M | $879M | $821M | — | $766M | $751M | $717M | — |
| Operating income | $500M | $492M | $447M | — | $426M | $417M | $387M | — |
| Net income | $399M | $393M | $349M | — | $365M | $345M | $311M | — |
| EPS (diluted) | $2.74 | $2.68 | $2.37 | — | $2.48 | $2.34 | $2.11 | — |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.66B | $1.42B | $1.38B | $1.21B | $933M | $522M | $426M | $238M |
| Inventory | $912M | $922M | $946M | $928M | $863M | $882M | $918M | $822M |
| Total current assets | $4.06B | $3.82B | $3.63B | $3.51B | $3.21B | $2.84B | $2.64B | $2.36B |
| Total assets | $8.78B | $8.50B | $8.31B | $8.17B | $7.57B | $7.14B | $7.22B | $6.87B |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $2.29B | $2.18B | $2.19B | $2.21B | $2.02B | $1.89B | $2.03B | $2.01B |
| Total equity | $6.49B | $6.32B | $6.12B | $5.97B | $5.55B | $5.25B | $5.20B | $4.86B |